List of Research Support

NIH/NIAID R01 AI116292-01  (PI: Florian Hladik)
05/01/15 – 04/30/20
Systems and Carcinogenic Impact Assessment of Topical Microbicides on the Human Mucosa
Several drugs, including NRTIs like tenofovir and non-NRTIs like dapivirine, are being tested for vaginal or rectal application to prevent sexual HIV transmission. However, NRTI drugs have side effects that could undermine their effectiveness and cause serious safety concerns with long-term, topical use. In this proposal, we study these side effects, with a particular focus on tenofovir’s possibly carcinogenic effects at the currently-tested concentrations, and determine whether non-NRTIs could be a safer alternative.

NIH/NIDA R01 DA040386-01  (PI: Florian Hladik)
07/01/15 – 06/30/20
Extracellular Vesicles in Semen and Genital HIV Infection and Immunity during Heroin Addiction and Medication-assisted Treatment (MAT) with Methadone or Buprenorphine
In this project, we study how opioids and extracellular vesicles in semen, alone or in conjunction, impact sexual HIV transmission and immunity to infection. These studies may enable the design of better HIV preventatives (vaccines and microbicides) and inform MAT drug choice in different clinical settings. We will also learn more about the tolerogenic mechanisms allowing conception, as well as opioid immunobiology, with implications for the clinical management of infections in persons who use drugs.

AmfAR 109541-61-RGRL   (PIs: Keith Jerome, Kim Woodrow, Florian Hladik, Joshua Schiffer)
02/01/17 – 01/31/21
Targeted nanaocarriers to accelerate depletion of the HIV reservoir
The goal of this project is to evaluate nanoparticle-based delivery of latency reversing agents and antiproliferatives in a macaque model as a potential curative approach to HIV.

NIH/NIAID P01 AI030731-23  (PI: Anna Wald)
07/05/13 – 06/30/18
Clinical Epidemiology and Pathogenesis of Asymptomatic HSV Infection
Project 1: Incident HSV-2 and Genital Health in Kenyan Adolescent Girls: An Inception Cohort
The overall goal of this P01 is to understand the epidemiology, natural history and host-pathogen interactions in HSV-2 and HSV-1 infection.
Role: Co-Investigator / Project 1 Leader

U01 OD019746  (PI: Muneesh Tewari)
09/01/14 – 08/31/18
Reference Profiles of exRNA in Biofluids from Well-Defined Human Cohorts
This project seeks to characterize the spectrum of endogenously- and exogenously-derived extracellular RNAs present in body fluids of healthy individuals.
Role: Co-Investigator

NIH/NIAID R01 AI111738  (PI: Jairam Lingappa)
06/01/14 – 06/30/18
Quantifying the Impact of Genital Mucosal Inflammation on HIV-1 Acquisition Risk
Sexual acquisition of HIV-1 is likely accentuated by inflammatory mediators released from genital tissues. Such mediators could be targets for novel HIV-1 prevention interventions. In this study, existing samples and data from African HIV-1 serodiscordant heterosexual couples (one partner HIV-1 infected and the other not) are utilized to quantify the most relevant mucosal mediators and test their power to predict HIV-1 infection.
Role: Co-Investigator

CDC U48 DP005013  (PIs: Jared Baeten & Jairam Lingappa)
09/30/14 – 09/30/19
Novel Studies of the Effect of Progestin-containing Contraception on HIV Risk
Women using certain forms of contraception may have enhanced HIV-1 risk. Using stored samples from African HIV-1 serodiscordant heterosexual couples, a series of innovative clinical and biological studies will be conducted to understand the effect of progestin-based contraception on HIV-1 transmission and disease.
Role: Co-Investigator

NIH/NIAID P30 AI027757-26  (PI: King Holmes)
06/01/13 – 05/31/18
Center for AIDS Research (CFAR). Core I: Immunology (Core Directors: De Rosa S & Stamatatos L)
One particular focus of the CFAR Immunology Core is Mucosal Immunology, where I provide expertise.
Role: Co-Investigator

NIH/NIAID R21/R33 AI094412-03  (PIs: Kim Woodrow & Florian Hladik)
06/01/11 – 05/31/16
Nanoparticle Microbicides for Delivery of Combination Antiretroviral Drugs (Microbicide Innovation Program)
The goal of this project is to develop, and implement in animal safety and efficacy studies, nanoparticle formulations of antiviral drugs that afford more flexibility in combining compounds with differing physicochemical properties for delivery as topical vaginal or rectal combination microbicides.

Bill & Melinda Gates Foundation OPP1032522  (PIs: Dayong Gao & Florian Hladik)
11/01/13 – 10/31/16
Development of Optimal Techniques for Cryopreservation of Human Mucosal Tissues for Use in Assessing HIV Vaccines and Microbicides
The overall goal of this study is the development of improved and reliable procedures to cryopreserve viable and functional cells and tissues from the mucosal sites of HIV transmission.

UM1 AI120716 (PIs: Rodney Ho & Ann Collier)
07/15/15 – 06/30/2020
Targeted Long-Acting Combination Antiretroviral Therapy (TLC-ART) Program
Scientific Project 3: Impact of Drug Formulations on Mucosal Immunity and HIV Resistance                                                                                                                                                             The long-term goal of the University of Washington TLC-ART program is to develop one or more safe, scalable, and well tolerated novel dosage formulations composed of long-acting antiretroviral combinations of drugs for treatment of HIV infection.
Role: Co-Investigator / Scientific Project 3 Leader

Preventing Preterm Birth Grant 12007 PI: David Eschenbach)
11/01/13 – 10/31/15
Bill & Melinda Gates Foundation
Global Alliance to Prevent Prematurity and Stillbirth (GAPPS): Determinants of Preterm Birth Associated with Bacterial Trafficking from the Lower Genital Tract
We contribute to this project by using mass cytometry (CYTOF) to study the phenotypes and activation states of neutrophil granulocytes in cervical cytobrushes from pregnant women.
Role: Co-Investigator

Divisional grant (Fred Hutch)  (PI: Florian Hladik)
07/01/14 – 06/30/15
Effect of NRTI drugs on immune activation and HIV latency
In this study, we investigate our hypothesis that NRTI drugs such as tenofovir slow the decay of cells containing integrated HIV provirus and thus paradoxically may interfere with HIV eradication.